427 BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030), a Randomised Phase 3 Trial of First-Line Atezolizumab with Bevacizumab and Platinum-Based Chemotherapy for Metastatic (stage IVB), Persistent or Recurrent Cervical Cancer